Awards

Women of Innovation 2014, Ilana Odess, CEO & Founder, Woven Orthopedic Technologies, LLC won the Entrepreneurial Innovation and Leadership Award at the CT Technology Council 2014 Women of Innovation Event
2014 Acquisition Fund Awards The 53,000 subscribers to Acquisition International acknowledge Anthony G. Viscogliosi and the firm of Viscogliosi Bros. LLC for its achievement of realizing exit proceeds for investors of more than $1.2 billion during the past decade. Healthcare Investment Firm of the Year - New York
Business Excellence Awards 2013 MEDICAL MERCHANT BANKING FIRM OF THE YEAR
Secondary Private Equity Investment characteristics and market outlook The secondary private equity market—where pre-existing private equity interests are bought and sold—has grown substantially since its beginnings in the 1980s. With transaction volume expected to reach $35 billion in 2012,1 the market continues to mature in its diversity of participants and complexity of transactions.
The M&A Advisor 2010, International Equity Financing of the Year The M&A Advisor, a leading investment banking publication, selected Dr.h.c. Anthony G. Viscogliosi, Founder, Chairman & CEO of Small Bone Innovations, Inc. (SBi), as a recipient of the International Equity Financing of the Year award. Dr.h.c. Anthony G. Viscogliosi, received the award for the $113 million private equity Series D funding of SBi. The funding, commenced in late 2008 and was completed in November 2009, a period of virtual paralysis in the capital markets.
2nd Annual International M&A Advisor Awards 2010, Equity Financing Deal of the Year in the Major Deal Category. Roger Aguinaldo, CEO of the M&A Advisor said, “With M&A activity increasing worldwide, each award recipient has excelled in their field and is truly deserving of the honor.”
New York College of Podiatric Medicine (NYCPM) 2010: Conferred upon the orthopedics industry benefactor, Dr.h.c. Anthony G. Viscogliosi, the honorary degree of Doctor of Humane Letters-Honors Causa. The degree is conferred as a way of honoring a distinguished visitor’s contributions to a specific field, or to society in general.

The M&A Advisor 2010, 40 Under 40 M&A Advisor Recognition Awards. Marc R. Viscogliosi, a Principal of New York merchant bank Viscogliosi Bros. LLC, , was recognized as a recipient of the inaugural 40 Under 40 Award. The publication noted, “Mr. Viscogliosi was responsible for several key investment opportunities in ‘non-fusion’ spinal devices and was one of the first Wall Street investment bankers to specialize in orthopedics. He has executed more than 190 transactions as principal or agent, buyer or seller.”
Medical Merchant Banking Firm of the Year Viscogliosi Bros. LLC Anthony G. Viscogliosi, Principal of Viscogliosi Bros. LLC (VB), describes the firm, its recent achievements and its reaction to winning the Business Excellence Award. VB was founded in New York in 1999 by Anthony, John and Marc Viscogliosi. The firm was the first investment banking and VC institution to focus exclusively on the emergent orthopaedic device industry.
Medical Merchant Banking Firm of the Year Viscogliosi Bros. LLC VB was founded in New York in 1999 by Anthony, John and Marc Viscogliosi. The firm was the first investment banking and VC institution to focus exclusively on the emergent orthopaedic device industry. Medical Merchant Banking Firm of the Year Viscogliosi Bros. LLC VB was formed to develop nascent technologies in orthopaedics – notably Spine Solutions Inc – the replacement spinal disk innovator that VB sold to Synthes in 2003 for $350 mm.
Medical Merchant Banking Firm of the Year USA Viscogliosi Bros. LLC As one of the first financiers to identify the global market potential for innovative joint replacement technologies, Anthony Viscogliosi has emerged as a pioneer in a $41 billion industry - 30% of which was generated by VC-backed companies.
Opportunity Abounds in Secondaries Market for Private Equity in Orthopaedic Devices Although stocks in the global $40 billion market for orthopaedic devices have recovered along with most of those in other market sectors, future growth in life sciences is under threat due to a widespread retreat from traditional VC financing that had been its life blood.